Abstract
Doxorubicin is reported to cause myelosuppression, with a white blood cell count nadir occurring between day 7 and day 10. Thrombocytopenia is less severe and occurs between days 3 and 8. This report presents an early onset of leukopenia (day 5) and a severe thrombocytopenia (4000 platelets/microliter) (day 6) associated with doxorubicin administration for treatment of recurrent tonsillar squamous cell carcinoma in a dog.
MeSH terms
-
Animals
-
Carcinoma, Squamous Cell / drug therapy
-
Carcinoma, Squamous Cell / veterinary*
-
Dog Diseases / drug therapy*
-
Dogs
-
Doxorubicin / adverse effects*
-
Doxorubicin / therapeutic use*
-
Leukocyte Count / veterinary
-
Leukopenia / chemically induced
-
Leukopenia / veterinary*
-
Male
-
Neoplasm Recurrence, Local / drug therapy
-
Neoplasm Recurrence, Local / veterinary
-
Platelet Count / veterinary
-
Thrombocytopenia / chemically induced
-
Thrombocytopenia / veterinary*
-
Time Factors
-
Tonsillar Neoplasms / drug therapy
-
Tonsillar Neoplasms / veterinary*